Open AccessTo what extent can we achieve mineral bone metabolism treatment targets suggested by the KDIGO guidelines among chronic kidney disease stage 3 – 5 non-dialysis patients?
Author(s) -
Mevlüt Tamer Dinçer,
Şeyda Gül Özcan,
Selma Alagöz,
Cebrail Karaca,
Sibel Hamarat Gulcicek,
Sinan Trabulus,
Meltem Pekpak,
Nurhan Seyahi
Publication year - 2022
Publication title -
clinical nephrology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.314
H-Index - 75
ISSN - 0301-0430
DOI - 10.5414/cn110733
Subject(s) - medicine , hyperphosphatemia , kidney disease , renal osteodystrophy , nephrology , hyperparathyroidism , dialysis , secondary hyperparathyroidism , hemodialysis , hypophosphatemia , vitamin d and neurology , parathyroid hormone , fibroblast growth factor 23 , intensive care medicine , calcium
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom